SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001144204-17-052744
Filing Date
2017-10-17
Accepted
2017-10-17 09:13:25
Documents
2
Group Members
DAN ORENDEXCEL PHARMA TECHNOLOGIES LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tv477092_sc13da.htm SC 13D/A 93280
2 EXHIBIT 1 tv477092_ex-1.htm EX-99.1 5223
  Complete submission text file 0001144204-17-052744.txt   100190
Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Subject) CIK: 0001447028 (see all company filings)

IRS No.: 980597776 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-85963 | Film No.: 171139999
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1 DEXCEL STREET OR AKIVA L3 30600000
Business Address 1 DEXCEL STREET OR AKIVA L3 30600000 972-4-636404
Dexxon Holdings Ltd. (Filed by) CIK: 0001636684 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D/A